Synopsis
Synopsis
0
VMF
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
1. Blastocarb
2. Carboplat
3. Carboplatin
4. Carbosin
5. Carbotec
6. Cbdca
7. Cis-diammine(cyclobutanedicarboxylato)platinum Ii
8. Ercar
9. Jm 8
10. Jm-8
11. Jm8
12. Nealorin
13. Neocarbo
14. Nsc 241240
15. Nsc-241240
16. Nsc241240
17. Paraplatin
18. Paraplatine
19. Platinwas
20. Ribocarbo
1. Paraplatin
2. Cbdca
3. Jm-8
4. Cis-diammine(1,1-cyclobutanedicarboxylato)platinum
5. Nsc 241240
6. Nsc-241240
7. Carboplatin [usan]
8. Bg3f62ond5
9. Cis-diammine(1,1-cyclobutanedicarboxylato) Platinum
10. Platinum, Diammine [1,1-cyclobutane-dicarboxylato(2-)-0,0']-,(sp-4-2)
11. Nsc-201345
12. Carboplatin [mi]
13. Carboplatin [inn]
14. Carboplatin [jan]
15. Carboplatin [hsdb]
16. Carboplatin [vandf]
17. Carboplatin [mart.]
18. Carboplatin [usp-rs]
19. Carboplatin [who-dd]
20. Cis-diamine(1,1-cyclobutanedicarboxylato)platinum(ii)
21. Carboplatin [ep Impurity]
22. Carboplatin [orange Book]
23. Carboplatin [ep Monograph]
24. Carboplatin [usp Impurity]
25. Carboplatin [usp Monograph]
26. Amy33401
27. S1215
28. Akos037515487
29. Ccg-268304
30. Ab01568249_01
31. Q415588
32. W-106301
33. Platinum, Diamine(1,1-cyclobutanedicarboxylato (2-)-o,o')-, (sp-4-2)-
Molecular Weight | 371.25 g/mol |
---|---|
Molecular Formula | C6H12N2O4Pt |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 0 |
Exact Mass | 371.044501 g/mol |
Monoisotopic Mass | 371.044501 g/mol |
Topological Polar Surface Area | 82.3 Ų |
Heavy Atom Count | 13 |
Formal Charge | 0 |
Complexity | 153 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 4 |
1 of 2 | |
---|---|
Drug Name | Carboplatin |
PubMed Health | Carboplatin (Injection) |
Drug Classes | Antineoplastic Agent |
Drug Label | Carboplatin injection is supplied as a sterile, pyrogen-free, 10 mg/mL aqueous solution of carboplatin. Carboplatin is a platinum coordination compound. The chemical name for carboplatin is platinum, diammine [1,1-cyclobutane-dicarboxylato(2-)-0,0... |
Active Ingredient | Carboplatin |
Dosage Form | Injectable |
Route | Iv (infusion) |
Strength | 450mg/45ml (10mg/ml); 150mg/15ml (10mg/ml); 600mg/60ml (10mg/ml); 1gm/100ml (10mg/ml); 50mg/5ml (10mg/ml) |
Market Status | Prescription |
Company | Pliva Lachema; Actavis Elizabeth; Fresenius Kabi Usa; Hospira; Mylan Institutional; Fresenius Kabi Oncol; Ebewe Pharma; Pharmachemie Bv; Onco Therapies; Teva Pharms Usa; Eurohlth Intl; Sagent Pharms; Cipla; Sun Pharma Global; Akorn |
2 of 2 | |
---|---|
Drug Name | Carboplatin |
PubMed Health | Carboplatin (Injection) |
Drug Classes | Antineoplastic Agent |
Drug Label | Carboplatin injection is supplied as a sterile, pyrogen-free, 10 mg/mL aqueous solution of carboplatin. Carboplatin is a platinum coordination compound. The chemical name for carboplatin is platinum, diammine [1,1-cyclobutane-dicarboxylato(2-)-0,0... |
Active Ingredient | Carboplatin |
Dosage Form | Injectable |
Route | Iv (infusion) |
Strength | 450mg/45ml (10mg/ml); 150mg/15ml (10mg/ml); 600mg/60ml (10mg/ml); 1gm/100ml (10mg/ml); 50mg/5ml (10mg/ml) |
Market Status | Prescription |
Company | Pliva Lachema; Actavis Elizabeth; Fresenius Kabi Usa; Hospira; Mylan Institutional; Fresenius Kabi Oncol; Ebewe Pharma; Pharmachemie Bv; Onco Therapies; Teva Pharms Usa; Eurohlth Intl; Sagent Pharms; Cipla; Sun Pharma Global; Akorn |
Antineoplastic Agents
Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)
Cross-Linking Reagents
Reagents with two reactive groups, usually at opposite ends of the molecule, that are capable of reacting with and thereby forming bridges between side chains of amino acids in proteins; the locations of naturally reactive areas within proteins can thereby be identified; may also be used for other macromolecules, like glycoproteins, nucleic acids, or other. (See all compounds classified as Cross-Linking Reagents.)
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
GDUFA
DMF Review : Reviewed
Rev. Date : 2015-02-13
Pay. Date : 2015-02-02
DMF Number : 7145
Submission : 1987-09-17
Status : Active
Type : II
Certificate Number : R1-CEP 2004-104 - Rev 03
Issue Date : 2023-03-27
Type : Chemical
Substance Number : 1081
Status : Valid
Registration Number : 222MF10101
Registrant's Address : 435 Devon Park Drive, Suite 400, Wayne, Pennsylvania 19087 USA
Initial Date of Registration : 2010-03-18
Latest Date of Registration : --
NDC Package Code : 49812-0010
Start Marketing Date : 2014-01-14
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Shanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.
GDUFA
DMF Review : Reviewed
Rev. Date : 2012-12-24
Pay. Date : 2012-12-03
DMF Number : 17659
Submission : 2004-09-08
Status : Active
Type : II
Certificate Number : R1-CEP 2000-375 - Rev 04
Issue Date : 2022-04-13
Type : Chemical
Substance Number : 1081
Status : Valid
Available Reg Filing : ASMF |
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 16664
Submission : 2003-06-20
Status : Active
Type : II
Certificate Number : CEP 2003-155 - Rev 03
Issue Date : 2023-12-14
Type : Chemical
Substance Number : 1081
Status : Valid
Date of Issue : 2022-06-08
Valid Till : 2025-07-25
Written Confirmation Number : WC-0159
Address of the Firm :
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 15938
Submission : 2002-04-18
Status : Active
Type : II
Certificate Number : R1-CEP 2002-129 - Rev 01
Issue Date : 2008-09-16
Type : Chemical
Substance Number : 1081
Status : Valid
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-09-23
Pay. Date : 2014-03-06
DMF Number : 28047
Submission : 2014-03-10
Status : Active
Type : II
Certificate Number : R1-CEP 2009-264 - Rev 03
Issue Date : 2019-10-24
Type : Chemical
Substance Number : 1081
Status : Valid
Registration Number : 226MF10121
Registrant's Address : Calle 14, Nr. 229 (Lote 13), B1629MXA, Parque Industrial Pilar, Buenos Aires, Argentina
Initial Date of Registration : 2014-06-18
Latest Date of Registration : --
NDC Package Code : 72659-863
Start Marketing Date : 2017-01-02
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 29100
Submission : 2015-02-10
Status : Active
Type : II
Certificate Number : CEP 2009-383 - Rev 04
Issue Date : 2024-06-26
Type : Chemical
Substance Number : 1081
Status : Valid
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 23606
Submission : 2010-02-22
Status : Inactive
Type : II
Certificate Number : CEP 2010-285 - Rev 03
Issue Date : 2024-02-14
Type : Chemical
Substance Number : 1081
Status : Valid
GDUFA
DMF Review : Complete
Rev. Date : 2015-02-13
Pay. Date : 2015-02-02
DMF Number : 7145
Submission : 1987-09-17
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2012-12-24
Pay. Date : 2012-12-03
DMF Number : 17659
Submission : 2004-09-08
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 16916
Submission : 2003-10-21
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-09-28
Pay. Date : 2013-09-20
DMF Number : 15147
Submission : 2000-11-17
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 16709
Submission : 2003-07-15
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-04-17
Pay. Date : 2013-04-08
DMF Number : 21918
Submission : 2008-08-29
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 16280
Submission : 2002-12-02
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 15938
Submission : 2002-04-18
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 16664
Submission : 2003-06-20
Status : Active
Type : II
USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 9541
Submission : 1992-01-03
Status : Inactive
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Mirvetuximab was readily combined and well tolerated with standard dosing of carboplatin and bevacizumab, with a manageable adverse event (AE) profile as anticipated for this triplet based on the side effect profiles of each agent.
Lead Product(s): Mirvetuximab Soravtansine,Carboplatin,Bevacizumab
Therapeutic Area: Oncology Brand Name: IMGN853
Study Phase: Phase I/ Phase IIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 17, 2020
Lead Product(s) : Mirvetuximab Soravtansine,Carboplatin,Bevacizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Mirvetuximab was readily combined and well tolerated with standard dosing of carboplatin and bevacizumab, with a manageable adverse event (AE) profile as anticipated for this triplet based on the side effect profiles of each agent.
Brand Name : IMGN853
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 17, 2020
Details:
Zynyz (retifanlimab), is a PD-1 inhibitor antibody drug candidate, which is being evaluated in the late-stage trial studies for treating metastatic NSCLC.
Lead Product(s): Retifanlimab,Cisplatin,Carboplatin
Therapeutic Area: Oncology Brand Name: Zynyz
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2024
Lead Product(s) : Retifanlimab,Cisplatin,Carboplatin
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Incyte Announces Positive Phase 3 Retifanlimab Data with Chemotherapy in NSCLC
Details : Zynyz (retifanlimab), is a PD-1 inhibitor antibody drug candidate, which is being evaluated in the late-stage trial studies for treating metastatic NSCLC.
Brand Name : Zynyz
Molecule Type : Large molecule
Upfront Cash : Not Applicable
December 07, 2024
Details:
IMNN-001 is a DNA-based interleukin-12 (IL-12) immunotherapy, which is being evaluated in combination with bevacizumab for the treatement of advanced ovarian cancer.
Lead Product(s): IMNN-001,Bevacizumab,Carboplatin
Therapeutic Area: Oncology Brand Name: IMNN-001
Study Phase: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 25, 2024
Lead Product(s) : IMNN-001,Bevacizumab,Carboplatin
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
IMUNON Highlights Phase 2 Results for IMNN-001 in Advanced Ovarian Cancer
Details : IMNN-001 is a DNA-based interleukin-12 (IL-12) immunotherapy, which is being evaluated in combination with bevacizumab for the treatement of advanced ovarian cancer.
Brand Name : IMNN-001
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
November 25, 2024
Details:
Dimesna (LP-300) is a cancer causing TK’s proteins and receptors inactivator, is being investigated in non-small cell lung cancer (NSCLC) in never-smokers in both Japan.
Lead Product(s): LP-300,Pemetrexed,Carboplatin
Therapeutic Area: Oncology Brand Name: Dimesna
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 19, 2024
Lead Product(s) : LP-300,Pemetrexed,Carboplatin
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lantern Doses First Patient in Japan for Phase 2 HARMONIC™ LP-300 NSCLC Trial
Details : Dimesna (LP-300) is a cancer causing TK’s proteins and receptors inactivator, is being investigated in non-small cell lung cancer (NSCLC) in never-smokers in both Japan.
Brand Name : Dimesna
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 19, 2024
Details:
Cejemly (sugemalimab) is an anti-PD-L1 monoclonal antibody, which is indicated in combination with platinum-based chemotherapy as the first-line treatment for non-small cell lung cancer in adults.
Lead Product(s): Sugemalimab,Carboplatin,Pemetrexed
Therapeutic Area: Oncology Brand Name: Cejemly
Study Phase: ApprovedProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 31, 2024
Lead Product(s) : Sugemalimab,Carboplatin,Pemetrexed
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
CStone’s Sugemalimab Approved in UK for First-Line NSCLC Treatment
Details : Cejemly (sugemalimab) is an anti-PD-L1 monoclonal antibody, which is indicated in combination with platinum-based chemotherapy as the first-line treatment for non-small cell lung cancer in adults.
Brand Name : Cejemly
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 31, 2024
Details:
Keytruda (pembrolizumab) is an anti-PD-1 therapy, indicated for the first-line treatment of primary advanced or recurrent endometrial carcinoma in adults who are candidates for systemic therapy.
Lead Product(s): Pembrolizumab,Carboplatin,Paclitaxel
Therapeutic Area: Oncology Brand Name: Keytruda
Study Phase: ApprovedProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2024
Lead Product(s) : Pembrolizumab,Carboplatin,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Merck’s KEYTRUDA Gains Two Gynecologic Cancer Approvals in Europe
Details : Keytruda (pembrolizumab) is an anti-PD-1 therapy, indicated for the first-line treatment of primary advanced or recurrent endometrial carcinoma in adults who are candidates for systemic therapy.
Brand Name : Keytruda
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 24, 2024
Details:
The net proceeds will be used to fund the clinical development of CK-301 (cosibelimab), which is being evaluated in the late-stage clinical trial studies for the treatment of NSCLC.
Lead Product(s): Cosibelimab,Cisplatin,Carboplatin
Therapeutic Area: Oncology Brand Name: CK-301
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Alliance Global Partners
Deal Size: $8.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 20, 2024
Lead Product(s) : Cosibelimab,Cisplatin,Carboplatin
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Alliance Global Partners
Deal Size : $8.0 million
Deal Type : Public Offering
Fortress Biotech Prices $8M Direct Offering and Private Placements
Details : The net proceeds will be used to fund the clinical development of CK-301 (cosibelimab), which is being evaluated in the late-stage clinical trial studies for the treatment of NSCLC.
Brand Name : CK-301
Molecule Type : Large molecule
Upfront Cash : Undisclosed
September 20, 2024
Details:
Keytruda (pembrolizumab) in combination with carboplatin and paclitaxel, is indicated for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma.
Lead Product(s): Pembrolizumab,Carboplatin,Paclitaxel
Therapeutic Area: Oncology Brand Name: Keytruda
Study Phase: ApprovedProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2024
Lead Product(s) : Pembrolizumab,Carboplatin,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Merck's KEYTRUDA® Regimens Receive Positive CHMP for Gynecologic Cancers
Details : Keytruda (pembrolizumab) in combination with carboplatin and paclitaxel, is indicated for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma.
Brand Name : Keytruda
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 20, 2024
Details:
Rybrevant (amivantamab) is approved in combined with (carboplatin and pemetrexed) for treating adult patients with locally advanced or metastatic NSCLC with L858R substitution mutations.
Lead Product(s): Amivantamab,Carboplatin,Pemetrexed
Therapeutic Area: Oncology Brand Name: Rybrevant
Study Phase: ApprovedProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 19, 2024
Lead Product(s) : Amivantamab,Carboplatin,Pemetrexed
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
RYBREVANT® Plus Standard Care Approved for EGFR-Mutated Lung Cancer
Details : Rybrevant (amivantamab) is approved in combined with (carboplatin and pemetrexed) for treating adult patients with locally advanced or metastatic NSCLC with L858R substitution mutations.
Brand Name : Rybrevant
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 19, 2024
Details:
Rybrevant (amivantamab) is a fully-human EGFR-MET bispecific antibody. It is being evaluated for the treatment of EX19 Deletion Non-small Cell Lung Cancer.
Lead Product(s): Amivantamab,Pemetrexed,Carboplatin
Therapeutic Area: Oncology Brand Name: Rybrevant
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2024
Lead Product(s) : Amivantamab,Pemetrexed,Carboplatin
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
RYBREVANT® (amivantamab) Plus Chemotherapy Shows Positive Survival Trend in Lung Cancer
Details : Rybrevant (amivantamab) is a fully-human EGFR-MET bispecific antibody. It is being evaluated for the treatment of EX19 Deletion Non-small Cell Lung Cancer.
Brand Name : Rybrevant
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 14, 2024
1,1-Cyclobutane Dicarboxylic Acid
CAS Number : 5445-51-2
End Use API : Carboplatin
About The Company : MINAKEM is a cGMP custom manufacturer of small molecule API, HPAPI and steroids. All development and manufacturing activities are supported by highly skilled R&...
Diethyl-1,1-Cyclobutane Dicarboxylate
CAS Number : 3779-29-1
End Use API : Carboplatin
About The Company : MINAKEM is a cGMP custom manufacturer of small molecule API, HPAPI and steroids. All development and manufacturing activities are supported by highly skilled R&...
Cyclobutane-1,1-dicarboxylic acid
CAS Number : 5445-51-2
End Use API : Carboplatin
About The Company : Delta Finochem Pvt Ltd. is a privately owned and professionally managed company, accredited by WHO-GMP & ISO 9001:2015 (Year of establishment 1994) Delta Finoch...
Methyl 2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-fl...
CAS Number : 1235865-75-4
End Use API : Carboplatin
About The Company : Established in 2011 and situated in Hangzhou, Zhejiang, China, Hangzhou Longshine Bio-Tech CO., Ltd is dedicated to providing services for pharmaceutical and ch...
CDMP: (4'-Chloro-5,5-dimethyl-3,4, 5,6-tetrahydro[...
CAS Number : 1228780-72-0
End Use API : Carboplatin
About The Company : Established in 2011 and situated in Hangzhou, Zhejiang, China, Hangzhou Longshine Bio-Tech CO., Ltd is dedicated to providing services for pharmaceutical and ch...
NMBS: 3-Nitro-4-{[(oxan-4-yl)methyl]amino}benzene-...
CAS Number : 1228779-96-1
End Use API : Carboplatin
About The Company : Established in 2011 and situated in Hangzhou, Zhejiang, China, Hangzhou Longshine Bio-Tech CO., Ltd is dedicated to providing services for pharmaceutical and ch...
Naprod is a top player in Oncology & Anesthesia FDF through excellent innovation, discovery of new processes & high-quality production.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Liquid Injection
Dosage Strength : 50MG/5ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Naprod is a top player in Oncology & Anesthesia FDF through excellent innovation, discovery of new processes & high-quality production.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Liquid Injection
Dosage Strength : 150MG/15ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Naprod is a top player in Oncology & Anesthesia FDF through excellent innovation, discovery of new processes & high-quality production.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Liquid Injection
Dosage Strength : 450MG/45ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Regulatory Info : Generic
Registration Country : South Africa
Brand Name : Aspen Carboplatin 150mg
Dosage Form : INJ
Dosage Strength : 150mg/15ml
Packaging : 15X1mg/15ml
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : South Africa
Regulatory Info : Generic
Registration Country : South Africa
Brand Name : Aspen Carboplatin 450mg
Dosage Form : INJ
Dosage Strength : 450mg/45ml
Packaging : 45X1mg/45ml
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : South Africa
Regulatory Info :
Registration Country : Iran
Brand Name : Carbonatin
Dosage Form : Vial
Dosage Strength : 50MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Iran
Regulatory Info :
Registration Country : Iran
Brand Name : Carbonatin
Dosage Form : Vial
Dosage Strength : 150MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Iran
Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Injection
Dosage Strength : 50ML/5ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Injection
Dosage Strength : 150MG/15ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Injection
Dosage Strength : 450MG/45ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
RLD : No
TE Code : AP
Brand Name : CARBOPLATIN
Dosage Form : INJECTABLE;INTRAVENOUS
Dosage Strength : 150MG/15ML (10MG/ML)
Approval Date : 2017-02-09
Application Number : 206775
RX/OTC/DISCN : RX
RLD : No
TE Code : AP
RLD : No
TE Code :
Brand Name : CARBOPLATIN
Dosage Form : INJECTABLE;INTRAVENOUS
Dosage Strength : 150MG/15ML (10MG/ML)
Approval Date : 2004-10-21
Application Number : 77247
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code :
Brand Name : CARBOPLATIN
Dosage Form : INJECTABLE;INTRAVENOUS
Dosage Strength : 50MG/5ML (10MG/ML)
Approval Date : 2006-02-15
Application Number : 77266
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code :
Brand Name : CARBOPLATIN
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 150MG/VIAL
Approval Date : 2004-10-14
Application Number : 76099
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code : AP
Brand Name : CARBOPLATIN
Dosage Form : INJECTABLE;INTRAVENOUS
Dosage Strength : 50MG/5ML (10MG/ML)
Approval Date : 2004-10-14
Application Number : 76517
RX/OTC/DISCN : RX
RLD : No
TE Code : AP
RLD : No
TE Code :
Brand Name : CARBOPLATIN
Dosage Form : INJECTABLE;INTRAVENOUS
Dosage Strength : 450MG/45ML (10MG/ML)
Approval Date : 2005-06-14
Application Number : 77096
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code :
Brand Name : CARBOPLATIN
Dosage Form : INJECTABLE;INTRAVENOUS
Dosage Strength : 600MG/60ML (10MG/ML)
Approval Date : 2013-06-03
Application Number : 77096
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code :
Brand Name : CARBOPLATIN
Dosage Form : INJECTABLE;INTRAVENOUS
Dosage Strength : 150MG/15ML (10MG/ML)
Approval Date : 2008-12-02
Application Number : 78631
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code : AP
Brand Name : CARBOPLATIN
Dosage Form : INJECTABLE;INTRAVENOUS
Dosage Strength : 50MG/5ML (10MG/ML)
Approval Date : 2008-09-19
Application Number : 77926
RX/OTC/DISCN : RX
RLD : No
TE Code : AP
RLD : No
TE Code :
Brand Name : CARBOPLATIN
Dosage Form : INJECTABLE;INTRAVENOUS
Dosage Strength : 50MG/5ML (10MG/ML)
Approval Date : 2007-03-30
Application Number : 77389
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
Naprod is a top player in Oncology & Anesthesia FDF through excellent innovation, discovery of new processes & high-quality production.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Liquid Injection
Dosage Strength : 50MG/5ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Naprod is a top player in Oncology & Anesthesia FDF through excellent innovation, discovery of new processes & high-quality production.
Packaging :
Regulatory Info :
Dosage : Liquid Injection
Dosage Strength : 50MG/5ML
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Naprod is a top player in Oncology & Anesthesia FDF through excellent innovation, discovery of new processes & high-quality production.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Liquid Injection
Dosage Strength : 150MG/15ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Naprod is a top player in Oncology & Anesthesia FDF through excellent innovation, discovery of new processes & high-quality production.
Packaging :
Regulatory Info :
Dosage : Liquid Injection
Dosage Strength : 150MG/15ML
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Naprod is a top player in Oncology & Anesthesia FDF through excellent innovation, discovery of new processes & high-quality production.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Liquid Injection
Dosage Strength : 450MG/45ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Naprod is a top player in Oncology & Anesthesia FDF through excellent innovation, discovery of new processes & high-quality production.
Packaging :
Regulatory Info :
Dosage : Liquid Injection
Dosage Strength : 450MG/45ML
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Regulatory Info :
Registration Country : Iran
Brand Name : Carbonatin
Dosage Form : Vial
Dosage Strength : 50MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Iran
Packaging :
Regulatory Info :
Dosage : Vial
Dosage Strength : 50MG
Brand Name : Carbonatin
Approval Date :
Application Number :
Registration Country : Iran
Regulatory Info :
Registration Country : Iran
Brand Name : Carbonatin
Dosage Form : Vial
Dosage Strength : 150MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Iran
Packaging :
Regulatory Info :
Dosage : Vial
Dosage Strength : 150MG
Brand Name : Carbonatin
Approval Date :
Application Number :
Registration Country : Iran
Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Injection
Dosage Strength : 50ML/5ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.
Packaging :
Regulatory Info :
Dosage : Injection
Dosage Strength : 50ML/5ML
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Injection
Dosage Strength : 150MG/15ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.
Packaging :
Regulatory Info :
Dosage : Injection
Dosage Strength : 150MG/15ML
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Injection
Dosage Strength : 450MG/45ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.
Packaging :
Regulatory Info :
Dosage : Injection
Dosage Strength : 450MG/45ML
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Injection
Dosage Strength : 600MG/60ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.
Packaging :
Regulatory Info :
Dosage : Injection
Dosage Strength : 600MG/60ML
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Regulatory Info :
Registration Country : China
Brand Name :
Dosage Form : Injection
Dosage Strength : 10MG/ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : China
Packaging :
Regulatory Info :
Dosage : Injection
Dosage Strength : 10MG/ML
Brand Name :
Approval Date :
Application Number :
Registration Country : China
Related Excipient Companies
Dosage Form : Tablet
Grade : Oral
Application : Taste Masking
Excipient Details : Mannitol is used as a filler, bulking agent and taste masking agent in ODT formulations such as tablets.
Excipients by Applications
Global Sales Information
Market Place
Reply
05 Jun 2024
Reply
11 Mar 2024
Reply
11 Mar 2024
Reply
13 Dec 2023
Reply
24 May 2023
Reply
09 Mar 2022
Reply
18 Sep 2021
Reply
11 Aug 2021
Reply
28 Jan 2019
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Carboplatin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Carboplatin, including repackagers and relabelers. The FDA regulates Carboplatin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Carboplatin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Carboplatin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Carboplatin supplier is an individual or a company that provides Carboplatin active pharmaceutical ingredient (API) or Carboplatin finished formulations upon request. The Carboplatin suppliers may include Carboplatin API manufacturers, exporters, distributors and traders.
click here to find a list of Carboplatin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Carboplatin DMF (Drug Master File) is a document detailing the whole manufacturing process of Carboplatin active pharmaceutical ingredient (API) in detail. Different forms of Carboplatin DMFs exist exist since differing nations have different regulations, such as Carboplatin USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Carboplatin DMF submitted to regulatory agencies in the US is known as a USDMF. Carboplatin USDMF includes data on Carboplatin's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Carboplatin USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Carboplatin suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Carboplatin Drug Master File in Japan (Carboplatin JDMF) empowers Carboplatin API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Carboplatin JDMF during the approval evaluation for pharmaceutical products. At the time of Carboplatin JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Carboplatin suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Carboplatin Drug Master File in Korea (Carboplatin KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Carboplatin. The MFDS reviews the Carboplatin KDMF as part of the drug registration process and uses the information provided in the Carboplatin KDMF to evaluate the safety and efficacy of the drug.
After submitting a Carboplatin KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Carboplatin API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Carboplatin suppliers with KDMF on PharmaCompass.
A Carboplatin CEP of the European Pharmacopoeia monograph is often referred to as a Carboplatin Certificate of Suitability (COS). The purpose of a Carboplatin CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Carboplatin EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Carboplatin to their clients by showing that a Carboplatin CEP has been issued for it. The manufacturer submits a Carboplatin CEP (COS) as part of the market authorization procedure, and it takes on the role of a Carboplatin CEP holder for the record. Additionally, the data presented in the Carboplatin CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Carboplatin DMF.
A Carboplatin CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Carboplatin CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Carboplatin suppliers with CEP (COS) on PharmaCompass.
A Carboplatin written confirmation (Carboplatin WC) is an official document issued by a regulatory agency to a Carboplatin manufacturer, verifying that the manufacturing facility of a Carboplatin active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Carboplatin APIs or Carboplatin finished pharmaceutical products to another nation, regulatory agencies frequently require a Carboplatin WC (written confirmation) as part of the regulatory process.
click here to find a list of Carboplatin suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Carboplatin as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Carboplatin API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Carboplatin as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Carboplatin and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Carboplatin NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Carboplatin suppliers with NDC on PharmaCompass.
Carboplatin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Carboplatin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Carboplatin GMP manufacturer or Carboplatin GMP API supplier for your needs.
A Carboplatin CoA (Certificate of Analysis) is a formal document that attests to Carboplatin's compliance with Carboplatin specifications and serves as a tool for batch-level quality control.
Carboplatin CoA mostly includes findings from lab analyses of a specific batch. For each Carboplatin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Carboplatin may be tested according to a variety of international standards, such as European Pharmacopoeia (Carboplatin EP), Carboplatin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Carboplatin USP).
LOOKING FOR A SUPPLIER?